Published in Oncology (Williston Park) on December 01, 2010
Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: the underlying mechanisms and clinical management. Scientifica (Cairo) (2013) 1.28
CD8+ CD122+ regulatory T cells contain clonally expanded cells with identical CDR3 sequences of the T-cell receptor β-chain. Immunology (2013) 0.82
In vivo efficacy of nano hyaluronan-conjugated cisplatin for treatment of murine melanoma. J Drugs Dermatol (2014) 0.80
Ipilimumab, a promising immunotherapy with increased overall survival in metastatic melanoma? Dermatol Res Pract (2011) 0.80
CTLA-4-blocking immunotherapy with ipilimumab for advanced melanoma. Oncology (Williston Park) (2010) 0.79
Ipilimumab for advanced melanoma: let's not throw caution to the winds. Oncology (Williston Park) (2010) 0.77
Improving the therapeutic benefits of ipilimumab. Oncology (Williston Park) (2010) 0.75
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol (2014) 9.86
Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet (2012) 7.00
Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer Res (2004) 3.64
Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. J Transl Med (2010) 2.65
Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J Neurosurg (2012) 2.28
Advances in the systemic treatment of metastatic melanoma. Oncology (Williston Park) (2013) 2.05
High HSP90 expression is associated with decreased survival in breast cancer. Cancer Res (2007) 1.88
Automated quantitative analysis of tissue microarrays reveals an association between high Bcl-2 expression and improved outcome in melanoma. Cancer Res (2004) 1.80
Expression of Aurora A (but not Aurora B) is predictive of survival in breast cancer. Clin Cancer Res (2008) 1.50
Melanoma prognostic model using tissue microarrays and genetic algorithms. J Clin Oncol (2009) 1.33
Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survival. Cancer Res (2003) 1.31
Characterizing disease states from topological properties of transcriptional regulatory networks. BMC Bioinformatics (2006) 1.27
Suppressor role of activating transcription factor 2 (ATF2) in skin cancer. Proc Natl Acad Sci U S A (2008) 1.26
Metastatic myoepithelial carcinoma of the vulva treated with carboplatin and paclitaxel. Lancet Oncol (2006) 1.20
alphaB-crystallin as a marker of lymph node involvement in breast carcinoma. Cancer (2004) 1.20
Automated quantitative analysis of HDM2 expression in malignant melanoma shows association with early-stage disease and improved outcome. Cancer Res (2004) 1.18
Evaluating the expression and prognostic value of TRAIL-R1 and TRAIL-R2 in breast cancer. Clin Cancer Res (2005) 1.13
Multi-level targeting of the phosphatidylinositol-3-kinase pathway in non-small cell lung cancer cells. PLoS One (2012) 1.12
Expression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancer. Breast Cancer Res (2008) 1.11
Chemotherapy and biologic therapies for melanoma: do they work? Clin Dermatol (2009) 1.11
Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays. Hum Pathol (2009) 1.08
Vertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating melanoma. Clin Cancer Res (2010) 1.07
Phosphatidylinositol-3-kinase as a therapeutic target in melanoma. Clin Cancer Res (2009) 1.06
Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib. Clin Cancer Res (2009) 1.03
Expression of tumor necrosis factor--related apoptosis-inducing ligand receptors 1 and 2 in melanoma. Clin Cancer Res (2006) 1.01
Increased expression of the E3 ubiquitin ligase RNF5 is associated with decreased survival in breast cancer. Cancer Res (2007) 0.98
Rab33A: characterization, expression, and suppression by epigenetic modification. J Invest Dermatol (2006) 0.98
C-Raf is associated with disease progression and cell proliferation in a subset of melanomas. Clin Cancer Res (2009) 0.97
Automated quantitative analysis of E-cadherin expression in lymph node metastases is predictive of survival in invasive ductal breast cancer. Clin Cancer Res (2005) 0.95
Advances in therapy for melanoma brain metastases. Clin Dermatol (2013) 0.95
CD70 expression patterns in renal cell carcinoma. Hum Pathol (2012) 0.92
Melanoma brain metastases: is it time to reassess the bias? Curr Probl Cancer (2011) 0.90
Driver mutations in melanoma: lessons learned from bench-to-bedside studies. Curr Oncol Rep (2012) 0.89
Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer. J Transl Med (2011) 0.88
Vascularity of primary and metastatic renal cell carcinoma specimens. J Transl Med (2013) 0.86
In vitro studies of dasatinib, its targets and predictors of sensitivity. Pigment Cell Melanoma Res (2011) 0.83
Benefits of biomarker selection and clinico-pathological covariate inclusion in breast cancer prognostic models. Breast Cancer Res (2010) 0.83
Immunotherapy for metastatic melanoma. J Cell Biochem (2012) 0.81
Case Report: response to ipilimumab in a patient with HIV with metastatic melanoma. J Clin Oncol (2011) 0.81
Expression of drug targets in primary and matched metastatic renal cell carcinoma tumors. BMC Clin Pathol (2013) 0.81
Molecular alternations in uveal melanoma. Curr Probl Cancer (2011) 0.80
Vertical pathway targeting in cancer therapy. Adv Pharmacol (2012) 0.80
Expression of drug targets in patients treated with sorafenib, carboplatin and paclitaxel. PLoS One (2013) 0.78
Studies of NVP-BEZ235 in melanoma. Curr Cancer Drug Targets (2013) 0.78
Assessing expression of apoptotic markers using large cohort tissue microarrays. Methods Mol Biol (2008) 0.77
Drug targets and predictive biomarkers in the management of metastatic melanoma. Pharmgenomics Pers Med (2012) 0.77
Radiation sensitivity and sensitization in melanoma. Pigment Cell Melanoma Res (2013) 0.76
Sarcoidosis Following Anti-PD-1 and Anti-CTLA-4 Therapy for Metastatic Melanoma. J Immunother (2017) 0.75
From the Guest Editors: Recent Advances and Evolving Challenges in Treating Unresectable Melanoma. Cancer J (2017) 0.75